Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | TRPC3 | Q13507 | 3/20 | 0.36 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724005 | 0.89 | HTR2C (0.44) | HTR2CHPGDRAB9AALDH1A1HSD17B10 | |
| SCHEMBL5725358 | 0.89 | HTR2C (0.42) | HTR2CHPGDRAB9AALDH1A1HSD17B10 | |
| SCHEMBL5723590 | 0.88 | HTR2C (0.46) | HTR2CHPGDRAB9AALDH1A1HSD17B10 | |
| SCHEMBL5724485 | 0.85 | TSHR (0.44) | HTR2CHPGDRAB9ATRPC3TRPC6 | |
| SCHEMBL5724039 | 0.85 | HTR2C (0.50) | HTR2CRAB9AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5724396 | 0.83 | HRH3 (0.37) | HTR2CCNR2HPGDRAB9AL3MBTL1 | |
| SCHEMBL5724329 | 0.83 | HPGD (0.35) | CNR2HPGDRAB9ATRPC3TRPC6 | |
| SCHEMBL5724462 | 0.79 | HRH3 (0.40) | HTR2CTRPC3TRPC6HRH3 | |
| SCHEMBL5723994 | 0.77 | HRH3 (0.46) | RAB9AL3MBTL1HRH3NPC1SMN1; SMN2 | |
| SCHEMBL5724414 | 0.74 | SCD (0.36) | HTR2CCNR2HPGDRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | HTR2C 4623/4885CNR2 1743/4885HPGD 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.